3-(4-Hydroxymethylbenzoyl)-1-pentylindole is a synthetic cannabinoid. It is planned to be scheduled (in group I-N) in Poland.http://www.mz.gov.pl/wwwmz/index?mr=q491&ms=382&ml=pl&mi=382&mx=0&mt=&my=131&ma=030747 http://www.mz.gov.pl/wwwfiles/ma_struktura/docs/ustawa_narkoman_201209171553.pdf "[E]kspertyza [opracowana] przez Katedrę i Zakład Farmakologii Doświadczalnej i Klinicznej Warszawskiego Uniwersytetu Medycznego [...] potwierdziła zasadność objęcia kontrolą ustawową [...] syntetycznych kanabinoidów: JWH-015, JWH-098, JWH-251, JWH-307, AM-2201, 3-(4-hydroksymetylobenzoilo)-1-pentyloindol" ("Department of Experimental and Clinical Pharmacology of Medical University of Warsaw evaluated that synthetic cannabinoids JWH-015, JWH-098, JWH-251, JWH-307, AM-2201, 3-(4-hydroxymethylbenzoyl)-1-pentylindole need to be scheduled.", accessed 30 April 2013) It has been reported to the EMCDDA and Europol for the first time in 2010 under the terms of European Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk-assessment and control of new psychoactive substances.
See also Synthetic cannabis
References